人类白细胞抗原变异与检查点抑制剂不良事件相关
这项前瞻性观察性单中心研究纳入102例接受检查点抑制剂治疗的转移性非小细胞肺癌或转移性黑色素瘤患者,58%发生至少一种免疫相关不良事件,以瘙痒和皮疹最多见。HLA-DRB1*11:01与瘙痒显著相关(OR=4.53,P<.01),HLA-DQB1*03:01与结肠炎呈名义显著相加关联(OR=3.94,P=.017)。
要点
- 102例接受检查点抑制剂治疗的患者中59例(58%)发生至少一种免疫相关不良事件。
- 瘙痒32例(54%)、皮疹24例(41%)在发生免疫相关不良事件的患者中比例最高。
- HLA-DRB1*11:01与瘙痒相关(OR=4.53,P<.01),HLA-DQB1*03:01与结肠炎名义显著相关(OR=3.94,P=.017)。
核心结论
- 两个已知 predispose 自身免疫病的HLA等位基因与治疗期间瘙痒或结肠炎的发生相关,提示免疫相关不良事件存在遗传病因。
- 作者认为需要更大规模的全基因组关联研究来证实这些发现。
研究设计与样本
- 前瞻性观察性单中心研究,纳入接受抗PD-1、抗CTLA4或两者联合治疗的转移性非小细胞肺癌或转移性黑色素瘤患者。
- 共纳入102例患者,中位年龄68岁(范围62-74岁)。
- 数据收集时间范围为2016年7月15日至2018年5月10日。
- 通过下一代测序进行HLA分型。
主要发现
- 102例患者中59例(58%)发生一种或多种免疫相关不良事件。
- 发生免疫相关不良事件的患者中,瘙痒32例(54%)、皮疹24例(41%)比例最高。
- 未发现单个HLA基因与所有免疫相关不良事件相关(所有P>.05)。
- HLA-DRB1*11:01与瘙痒显著相关(OR=4.53,X21,95=9.45,P<.01)。
- HLA-DQB1*03:01与结肠炎呈名义显著相加关联(OR=3.94,X21,95=5.67,P=.017)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者认为需要更大规模的全基因组关联研究来证实这些发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Checkpoint inhibitors (CIs) are highly effective but can induce severe immune-related adverse events (irAEs), which cannot be predicted. We investigated whether human leukocyte antigen (HLA) genes predispose to developing of irAEs during therapy and thus hold a predictive role. METHODS: We established a prospective observational single-centre study and collected data from patients with either metastatic non-small cell lung cancer (NSCLC) or metastatic melanoma, who were treated with anti-PD-1 (programmed cell death receptor 1), anti-CTLA4 (cytotoxic T-lymphocyte-associated protein 4) or both CIs combined. Data include irAEs and ranges from 15th July 2016 until 10th May 2018. In addition, we performed HLA typing via next generation sequencing. RESULTS: We enrolled 102 patients (median [range] age, 68 [62-74] years) with metastatic cancer in our study who received CI therapy. Of these patients, 59 (58%) developed one or more irAEs, among which pruritus (n = 32 (54%)) and rash (n = 24 (41%)) had the highest rates. We did not find evidence for a single HLA gene being associated with all irAEs (all P > .05). When assessing each irAE individually, we found a significant association between HLA-DRB1*11:01 and pruritus (OR = 4.53, X21,95 = 9.45, P < .01) as well as a nominally significant additive association between HLA-DQB1*03:01 and colitis (OR = 3.94, X21,95 = 5.67, P = .017). CONCLUSIONS: The presence of two HLA alleles that are known to predispose to autoimmune diseases were associated with the development of pruritus or colitis during therapy, suggesting a genetic aetiology of irAEs. Larger genome-wide association studies should be performed to confirm our findings.
引用
- Hasan Ali O, Berner F, Bomze D, et al. Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors. Eur J Cancer. 2018. PMID: 30529903. doi:10.1016/j.ejca.2018.11.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。